Shares of Globus Medical (GMED) reached a new 52-week high of $67.37 on May 22 before closing the session marginally lower at $67.15. In the past year, this Zacks Rank #3 (Hold) stock has rallied 25.8% compared with the 12.1% growth of the industry and the S&P 500 composite's rise of 29.5%. Globus Medical has an expected 2024 sales growth rate of 57.8%. Earnings for the year are projected to increase by 20.7% compared with the industry's 13.3%. The company topped earnings estimates in each of the trailing f ...

Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is bett ...

Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Penumbra (PEN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision tr ...

Have you been paying attention to shares of Globus Medical (GMED) ? Shares have been on the move with the stock up 16.2% over the past month. The stock hit a new 52-week high of $65.74 in the previous session. Globus Medical has gained 15.8% since the start of the year compared to the 3.1% move for the Zacks Medical sector and the 4.9% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our ear ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

Globus Medical, Inc. (GMED) reported adjusted earnings per share (EPS) of 72 cents in the first quarter of 2024, which beat the Zacks Consensus Estimate by 30.9%. The metric increased 35.8% year over year.The adjusted EPS excludes certain non-recurring expenses and benefits like the amortization of intangibles, acquisition-related costs/licensing and provision for litigation, among others.Without adjustments, the company registered a GAAP diluted loss of 5 cents compared with the year-ago EPS of 48 cents.Re ...

财务数据和关键指标变化 - 2024年第一季度销售额为6.067亿美元,同比增长119.3% [7] - 2024年第一季度非GAAP每股收益为0.72美元,同比增长36.4% [46] - 2024年第一季度调整后EBITDA率为27.5%,自由现金流为2380万美元 [48] 各条业务线数据和关键指标变化 - 美国脊柱业务同比增长100%,主要得益于产品组合的优势、竞争性销售人员的招聘以及机器人带动的植入量增加 [11] - 国际脊柱业务同比增长193%,公司在2022和2023年加大了在人员、产品和设备方面的投资 [24] - 创伤和专科骨科业务同比增长308%,得益于创伤业务的强劲表现和NuVasive专科骨科业务的快速增长 [25] - 机器人和成像系统销售同比增长27.5%,创下历史新高 [23] 各个市场数据和关键指标变化 - 美国销售额同比增长106.3%,国际销售额同比增长190.7% [52][53] - 国际市场主要增长来自西班牙、意大利、比利时、爱尔兰、德国、沙特阿拉伯和波兰等重点国家的脊柱植入物业务 [53] 公司战略和发展方向及行业竞争 - 公司将更多关注于实现持续盈利增长和稳定的自由现金流,而不是仅关注调整后EBITDA [10] - 公司将继续专注于脊柱业务,同时也在向肌肉骨骼技术公司转型,推出新的电动工具、机器人等产品 [119][120] - 公司认为未来竞争对手的新机器人产品不会对公司构成重大威胁,公司有信心凭借自身的最佳机器人技术和创新产品组合保持竞争优势 [174][175] 管理层对经营环境和未来前景的评论 - 公司对2024年的业绩保持谨慎乐观态度,预计全年销售额将增长2.7%-3.7%,非GAAP每股收益将增长18.5%-22.8% [71][72] - 公司认为整合工作进展顺利,预计到第三季度将更加确定是否需要保留之前提到的150万美元的协同损失 [141][142] - 公司有信心未来几年能够将调整后EBITDA率提升至中高30%的水平,通过成本协同和收入增长实现 [160][161][165] 问答环节重要的提问和回答 问题1 **Matt Blackman提问** 询问公司是否会降低之前提到的150万美元的协同损失预期 [79] **Keith Pfeil回答** 公司目前没有降低该预期,但随着业务表现的持续改善,公司对全年业绩更加乐观,未来可能会调整这一预期 [80][81] 问题2 **Kendall提问** 询问公司如何应对未来可能进入市场的竞争对手机器人产品 [90] **Daniel Scavilla和Keith Pfeil回答** 公司有信心凭借自身的最佳机器人技术和创新产品组合保持竞争优势,同时也在不断投入研发推出新产品以保持领先地位 [91][92][174][175] 问题3 **Craig Bijou提问** 询问公司何时可能取消之前提到的150万美元协同损失预期 [141] **Daniel Scavilla和Keith Pfeil回答** 公司预计到第三季度时可能会更加确定是否需要保留该预期 [142][143][144]

For the quarter ended March 2024, Globus Medical (GMED) reported revenue of $606.67 million, up 119.3% over the same period last year. EPS came in at $0.72, compared to $0.53 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $586.66 million, representing a surprise of +3.41%. The company delivered an EPS surprise of +30.91%, with the consensus EPS estimate being $0.55.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Globus Medical (GMED) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 30.91%. A quarter ago, it was expected that this medical device company would post earnings of $0.59 per share when it actually produced earnings of $0.60, delivering a surprise of 1.69%.Over the last four quarters, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (cid:0) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-37449 ...